Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

Similar articles for PubMed (Select 25017614)

1.

Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.

Ghanizadeh A, Rezaee Z, Dehbozorgi S, Berk M, Akhondzadeh S.

Psychiatry Res. 2014 Nov 30;219(3):431-5. doi: 10.1016/j.psychres.2014.06.039. Epub 2014 Jun 27.

PMID:
25017614
2.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
3.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
4.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
5.

Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.

Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.

Eur Neuropsychopharmacol. 2014 Jun;24(6):846-55. doi: 10.1016/j.euroneuro.2014.02.001. Epub 2014 Feb 25.

PMID:
24636461
6.

A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.

Farokhnia M, Sabzabadi M, Pourmahmoud H, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Akhondzadeh S.

Psychopharmacology (Berl). 2014 Feb;231(3):533-42. doi: 10.1007/s00213-013-3261-z. Epub 2013 Sep 8.

PMID:
24013610
7.

Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.

Akhondzadeh S, Ghayyoumi R, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR, Naderi M, Ghebleh F, Tabrizi M, Rezazadeh SA.

Psychopharmacology (Berl). 2011 Feb;213(4):809-15. doi: 10.1007/s00213-010-2044-z. Epub 2010 Oct 15.

PMID:
20949350
8.

A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.

Xiao SF, Xue HB, Li X, Chen C, Li GJ, Yuan CM, Zhang MY.

Neurosci Bull. 2011 Aug;27(4):258-68. doi: 10.1007/s12264-011-1417-6.

PMID:
21788997
9.

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.

Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF.

J Child Adolesc Psychopharmacol. 2009 Dec;19(6):611-21. doi: 10.1089/cap.2008.0144.

PMID:
20035579
10.

Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.

Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S.

Daru. 2014 Jul 10;22:55. doi: 10.1186/2008-2231-22-55.

11.

Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.

Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, Shams-Alizadeh N, Mohammad-Karimi M, Esfandiari GR, Hajiaghaee R, Akhondzadeh S.

J Psychiatr Res. 2013 Apr;47(4):472-8. doi: 10.1016/j.jpsychires.2013.01.011. Epub 2013 Jan 30.

PMID:
23375406
12.

Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.

Rezaei F, Mohammad-Karimi M, Seddighi S, Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H, Hajiaghaee R, Tabrizi M, Akhondzadeh S.

J Clin Psychopharmacol. 2013 Jun;33(3):336-42. doi: 10.1097/JCP.0b013e31828b50a7.

PMID:
23609382
13.

Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.

Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, Abi-Saab W, Baker J, Redden L, Greco N, Saltarelli M.

Neuropsychopharmacology. 2009 Apr;34(5):1330-8. doi: 10.1038/npp.2008.209. Epub 2008 Dec 3.

14.

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.

Schizophr Res. 2014 Aug;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040. Epub 2014 Jul 1.

PMID:
24994555
15.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
16.

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.

Am J Psychiatry. 2005 Jan;162(1):130-6.

PMID:
15625211
17.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
18.

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.

Casey DE, Sands EE, Heisterberg J, Yang HM.

Psychopharmacology (Berl). 2008 Oct;200(3):317-31. doi: 10.1007/s00213-008-1207-7. Epub 2008 Jul 4.

PMID:
18597078
19.

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K.

Am J Psychiatry. 2003 Jun;160(6):1125-32.

PMID:
12777271
20.

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2008 Mar;23(2):79-86.

PMID:
17972359
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk